Ketamine's antidepressant effect: Focus on ketamine mechanisms of action;Effet antidépresseur de la kétamine: revue de la littérature sur les mécanismes d'action de la kétamine

Encephale

Volumn 40, Issue 1, 2014, Pages 48-55

  De Maricourt, P ^a,b   Jay, T ^b   Goncalves P ^c   Loo H ^a   Gaillard, R ^a,b  

^a CENTRE HOSPITALIER SAINTE ANNE   (France)

^b INSERM   (France)

^c Clinique du Bois Bondy   (France)

Author keywords

Glutamate; Ketamine; Major depressive disorder; NMDA receptors; Treatment resistant depression

Indexed keywords

DÉPRESSION; DÉPRESSION RÉSISTANTE; GLUTAMATE; KETAMINE; KÉTAMINE; MAJOR DEPRESSIVE DISORDER; NMDA; NMDA RECEPTORS; TREATMENT-RESISTANT DEPRESSION;

ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; ELONGATION FACTOR 2 KINASE; GLYCOGEN SYNTHASE KINASE 3; GYRUS CINGULI; HUMANS; KETAMINE; NEURONAL PLASTICITY; RECEPTORS, NEUROTRANSMITTER; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION; TOR SERINE-THREONINE KINASES;

EID: 84894454406     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.encep.2013.09.002     Document Type: Article

References (82)

1. WHO. The global burden of disease: 2004 update (Internet). WHO. (cité 22 janv 2013). Disponible sur: http://www.who.int/healthinfo/ global-burden-disease/2004-report-update/en/index.html.
2. S.M. Stahl Stahl's essential psychopharmacology: neuroscientific basis and practical applications 2008 Cambridge University Press Cambridge
3. J. Schüttler, and H. Schwilden Modern anesthetics 2008 Springer Berlin
4. S.A. Bergman Ketamine: review of its pharmacology and its use in pediatric anesthesia Anesth Prog 46 1 1999 10 20
5. R. Quibell, E.E. Prommer, and M. Mihalyo et al. Ketamine J Pain Symptom Manage 41 3 2011 640 649
6. J.H. Krystal, L.P. Karper, and J.P. Seibyl et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses Arch Gen Psychiatry 51 3 1994 199 214
7. J.W. Moore, D.C. Turner, and P.R. Corlett et al. Ketamine administration in healthy volunteers reproduces aberrant agency experiences associated with schizophrenia Cogn Neuropsychiatry 2011 1 18
8. P.R. Corlett, G.D. Honey, and J.H. Krystal et al. Glutamatergic model psychoses: prediction error, learning, and inference Neuropsychopharmacology 36 1 2011 294 315
9. R.M. Berman, A. Cappiello, and A. Anand et al. Antidepressant effects of ketamine in depressed patients Biol Psychiatry 47 4 2000 351 354
10. C.A. Zarate Jr., J.B. Singh, and P.J. Carlson et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression Arch Gen Psychiatry 63 8 2006 856 864
11. M. Aan Het Rot, C.A. Zarate Jr., and D.S. Charney et al. Ketamine for depression: where do we go from here? Biol Psychiatry 72 7 2012 537 547
12. I. Duguid, and P.J. Sjöström Novel presynaptic mechanisms for coincidence detection in synaptic plasticity Curr Opin Neurobiol 16 3 2006 312 322
13. B. Moghaddam, B. Adams, and A. Verma et al. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex J Neurosci 17 8 1997 2921 2927
14. M.C. Quirk, D.L. Sosulski, and C.E. Feierstein et al. A defined network of fast-spiking interneurons in orbitofrontal cortex: responses to behavioral contingencies and ketamine administration Front Syst Neurosci 3 2009 13
15. R.S. Duman, N. Li, and R.-J. Liu et al. Signaling pathways underlying the rapid antidepressant actions of ketamine Neuropharmacology 62 1 2012 35 41
16. S. Maeng, C.A. Zarate Jr., and J. Du et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3- hydroxy-5-methylisoxazole-4-propionic acid receptors Biol Psychiatry 63 4 2008 349 352
17. N. Li, R.-J. Liu, and J.M. Dwyer et al. Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure Biol Psychiatry 69 8 2011 754 761
18. N. Li, B. Lee, and R.-J. Liu et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists Science 329 5994 2010 959 964
19. D. Cotter, D. Mackay, and G. Chana et al. Reduced neuronal size and glial cell density in area 9 of the dorsolateral prefrontal cortex in subjects with major depressive disorder Cereb Cortex 12 4 2002 386 394
20. C.A. Stockmeier, G.J. Mahajan, and L.C. Konick et al. Cellular changes in the postmortem hippocampus in major depression Biol Psychiatry 56 9 2004 640 650
21. J.J. Radley, A.B. Rocher, and M. Miller et al. Repeated stress induces dendritic spine loss in the rat medial prefrontal cortex Cereb Cortex 16 3 2006 313 320
22. W.C. Drevets Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders Curr Opin Neurobiol 11 2 2001 240 249
23. M.C. Denk, C. Rewerts, and F. Holsboer et al. Monitoring ketamine treatment response in a depressed patient via peripheral mammalian target of rapamycin activation Am J Psychiatry 168 7 2011 751 752
24. A.E. Autry, M. Adachi, and E. Nosyreva et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses Nature 475 7354 2011 91 95
25. C.N. Haile, J.W. Murrough, and D.V. Iosifescu et al. Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression Int J Neuropsychopharmacol 2013 [Epub ahead of print, PMID: 24103211]
26. R.-J. Liu, F.S. Lee, and X.-Y. Li et al. Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex Biol Psychiatry 71 11 2012 996 1005
27. G. Laje, N. Lally, and D. Mathews et al. Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients Biol Psychiatry 72 11 2012 e27 e28
28. E. Beurel, L. Song, and R.S. Jope Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice Mol Psychiatry 16 11 2011 1068 1070
29. R.J. Liu, M. Fuchikami, and J.M. Dwyer et al. GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine Neuropsychopharmacology 38 11 2013 2268 2277
30. X. Li, and R.S. Jope Is glycogen synthase kinase-3 a central modulator in mood regulation? Neuropsychopharmacology 35 11 2010 2143 2154
31. C. Yang, Z.-Q. Zhou, and Z.-Q. Gao et al. Acute increases in plasma mammalian target of rapamycin. Glycogen synthase kinase-3β, and eukaryotic elongation factor 2 phosphorylation after ketamine treatment in three depressed patients Biol Psychiatry 73 12 2012 e35 e36
32. J.A. Clements, and W.S. Nimmo Pharmacokinetics and analgesic effect of ketamine in man Br J Anaesth 53 1 1981 27 30
33. M. Carlsson, and A. Carlsson Interactions between glutamatergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and Parkinson's disease Trends Neurosci 13 7 1990 272 276
34. L.S. Kegeles, A. Abi-Dargham, and Y. Zea-Ponce et al. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia Biol Psychiatry 48 7 2000 627 640
35. S. Kapur, and P. Seeman NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia Mol Psychiatry 7 8 2002 837 844
36. E.K. Silberman, V.I. Reus, and D.C. Jimerson et al. Heterogeneity of amphetamine response in depressed patients Am J Psychiatry 138 10 1981 1302 1307
37. E. Haroon, C.L. Raison, and A.H. Miller Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior Neuropsychopharmacology 37 1 2012 137 162
38. A.M. Myint, and Y.K. Kim Cytokine-serotonin interaction through IDO: a neurodegeneration hypothesis of depression Med Hypotheses 61 5-6 2003 519 525
39. J. Steiner, M. Walter, and T. Gos et al. Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission? J Neuroinflammation 8 2011 94
40. S. Erhardt, C.K. Lim, and K.R. Linderholm et al. Connecting inflammation with glutamate agonism in suicidality Neuropsychopharmacology 38 5 2013 743 752
41. T. Taniguchi, and K. Yamamoto Anti-inflammatory effects of intravenous anesthetics on endotoxemia Mini Rev Med Chem 5 3 2005 241 245
42. T. Taniguchi, H. Kanakura, and Y. Takemoto et al. The anti-inflammatory effects of ketamine in endotoxemic rats during moderate and mild hypothermia Anesth Analg 98 4 2004 1114 1120
43. G. Hasler, J.W. Van der Veen, and T. Tumonis et al. Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy Arch Gen Psychiatry 64 2 2007 193 200
44. J.J. Yang, Z.Q. Zhou, and C. Yang Letter to the editor: does ketamine exert a fast-acting antidepressant effect via inhibition of pro-inflammatory cytokines? Psychol Med 41 8 2011 1787 [author reply 1787-1789]
45. C. Yang, Z. Zhou, and J. Shi et al. Ketamine may exert antidepressant effects via mediating the kynurenine pathway Expert Opin Ther Targets 15 12 2011 1423 1424
46. A.K. Walker, D.P. Budac, and S. Bisulco et al. NMDA receptor blockade by ketamine abrogates lipopolysaccharide-induced depressive-like behavior in C57BL/6 J mice Neuropsychopharmacology 38 9 2013 1609 1616
47. J. Steiner, B. Bogerts, and Z. Sarnyai et al. Bridging the gap between the immune and glutamate hypotheses of schizophrenia and major depression: Potential role of glial NMDA receptor modulators and impaired blood-brain barrier integrity World J Biol Psychiatry 13 7 2012 482 492
48. J.F.W. Deakin, J. Lees, and S. McKie et al. Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study Arch Gen Psychiatry 65 2 2008 154 164
49. J. Horacek, M. Brunovsky, and T. Novak et al. Subanesthetic dose of ketamine decreases prefrontal theta cordance in healthy volunteers: implications for antidepressant effect Psychol Med 40 9 2010 1443 1451
50. A.M. Hunter, B.O. Muthén, and I.A. Cook et al. Antidepressant response trajectories and quantitative electroencephalography (QEEG) biomarkers in major depressive disorder J Psychiatr Res 44 2 2010 90 98
51. H.S. Mayberg, A.M. Lozano, and V. Voon et al. Deep brain stimulation for treatment-resistant depression Neuron 45 5 2005 651 660
52. M. Bares, M. Brunovsky, and M. Kopecek et al. Changes in QEEG prefrontal cordance as a predictor of response to antidepressants in patients with treatment resistant depressive disorder: a pilot study J Psychiatr Res 41 3-4 2007 319 325
53. R.F. Bell Ketamine for chronic non-cancer pain Pain 141 3 2009 210 214
54. H. Schulte, A. Sollevi, and M. Segerdahl The synergistic effect of combined treatment with systemic ketamine and morphine on experimentally induced windup-like pain in humans Anesth Analg 98 6 2004 1574 1580
55. C.J. Woolf, and S.W. Thompson The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states Pain 44 3 1991 293 299
56. S. Ilkjaer, K.L. Petersen, and J. Brennum et al. Effect of systemic N-methyl-D-aspartate receptor antagonist (ketamine) on primary and secondary hyperalgesia in humans Br J Anaesth 76 6 1996 829 834
57. R. Gaillard, H. Lôo, and J.-P. Olie (Mental pain: is it a symptom?) Bull Acad Natl Med 194 3 2010 567 578 [discussion 578-581]
58. E. Olié, S. Guillaume, and I. Jaussent et al. Higher psychological pain during a major depressive episode may be a factor of vulnerability to suicidal ideation and act J Affect Disord 120 1-3 2010 226 230
59. N. Rijavec, and V.N. Grubic Depression and pain: often together but still a clinical challenge: a review Psychiatr Danub 24 4 2012 346 352
60. N.I. Eisenberger, M.D. Lieberman, and K.D. Williams Does rejection hurt? An FMRI study of social exclusion Science 302 5643 2003 290 292
61. J. Panksepp Neuroscience. Feeling the pain of social loss Science 302 5643 2003 237 239
62. N. DiazGranados, L.A. Ibrahim, and N.E. Brutsche et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder J Clin Psychiatry 71 12 2010 1605 1611
63. C.A. Zarate Jr., D. Mathews, and L. Ibrahim et al. A Randomized trial of a low-trapping nonselective n-methyl-d-aspartate channel blocker in major depression Biol Psychiatry 74 4 2013 257 264
64. G. Sanacora, M.A. Smith, and S. Pathak et al. Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects Mol Psychiatry 2013 [Epub ahead of print]
65. J. Burgdorf, X.-L. Zhang, and K.L. Nicholson et al. GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects Neuropsychopharmacology 38 7 2013 1374
66. A. Alt, E.S. Nisenbaum, and D. Bleakman et al. A role for AMPA receptors in mood disorders Biochem Pharmacol 71 9 2006 1273 1288
67. S. Farley, K. Apazoglou, and J.M. Witkin et al. Antidepressant-like effects of an AMPA receptor potentiator under a chronic mild stress paradigm Int J Neuropsychopharmacol 13 9 2010 1207 1218
68. J.C. Quirk, and E.S. Nisenbaum LY404187: a novel positive allosteric modulator of AMPA receptors CNS Drug Rev 8 3 2002 255 282
69. B. Legutko, X. Li, and P. Skolnick Regulation of BDNF expression in primary neuron culture by LY392098, a novel AMPA receptor potentiator Neuropharmacology 40 8 2001 1019 1027
70. F. Fumagalli, F. Calabrese, and A. Luoni et al. The AMPA receptor potentiator Org 26576 modulates stress-induced transcription of BDNF isoforms in rat hippocampus Pharmacol Res 65 2 2012 176 181
71. S.J. Mathew, H.K. Manji, and D.S. Charney Novel drugs and therapeutic targets for severe mood disorders Neuropsychopharmacology 33 9 2008 2080 2092
72. S.L. Gourley, J.W. Espitia, and G. Sanacora et al. Antidepressant-like properties of oral riluzole and utility of incentive disengagement models of depression in mice Psychopharmacology 219 3 2012 805 814
73. Y.S. Mineur, M.R. Picciotto, and G. Sanacora Antidepressant-like effects of ceftriaxone in male C57BL/6J mice Biol Psychiatry 61 2 2007 250 252
74. J.D. Rothstein, S. Patel, and M.R. Regan et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression Nature 433 7021 2005 73 77
75. A. Pilc, J.M. Wierońska, and P. Skolnick Glutamate-based antidepressants: preclinical psychopharmacology Biol Psychiatry 73 12 2013 1125 1130
76. M. Nakamoto, V. Nalavadi, and M.P. Epstein et al. Fragile X mental retardation protein deficiency leads to excessive mGluR5-dependent internalization of AMPA receptors Proc Natl Acad Sci U S A 104 39 2007 15537 15542
77. X. Li, A.B. Need, and M. Baez et al. Metabotropic glutamate 5 receptor antagonism is associated with antidepressant-like effects in mice J Pharmacol Exp Ther 319 1 2006 254 259
78. A. Pałucha-Poniewiera, and A. Pilc Involvement of mGlu5 and NMDA receptors in the antidepressant-like effect of acamprosate in the tail suspension test Prog Neuropsychopharmacol Biol Psychiatry 39 1 2012 102 106
79. S.J. Sukoff Rizzo, S.K. Leonard, and A. Gilbert et al. The metabotropic glutamate receptor 7 allosteric modulator AMN082: a monoaminergic agent in disguise? J Pharmacol Exp Ther 338 1 2011 345 352
80. A. Pałucha-Poniewiera, P. Brański, and T. Lenda et al. The antidepressant-like action of metabotropic glutamate 7 receptor agonist N. N'-bis(diphenylmethyl)-1,2-ethanediamine (AMN082) is serotonin-dependent J Pharmacol Exp Ther 334 3 2010 1066 1074
81. U.E. Lang, J. Heger, and M. Willbring et al. Immunosuppression using the mammalian target of rapamycin (mTOR) inhibitor everolimus: pilot study shows significant cognitive and affective improvement Transplant Proc 41 10 2009 4285 4288
82. T. Insel, B. Cuthbert, and M. Garvey et al. Research Domain Criteria (RDoC): toward a new classification framework for research on mental disorders Am J Psychiatry 167 2010 748 751